Can Hepatitis B surface antigen (HBsAg) ever become negative?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can HBsAg Become Negative?

Yes, HBsAg can become negative through spontaneous clearance, occurring at approximately 0.5% per year in chronic carriers, representing "resolved hepatitis B" with sustained loss of HBsAg, undetectable HBV DNA, and absence of active viral infection. 1

Mechanisms and Rates of HBsAg Clearance

Spontaneous clearance occurs naturally but slowly:

  • Approximately 0.5% of HBsAg carriers clear the antigen yearly 1
  • Most patients who clear HBsAg will subsequently develop anti-HBs antibodies 1
  • Clearance typically follows years of chronic infection, often after HBeAg seroconversion 1

Predictors of impending HBsAg clearance include:

  • Decreasing HBsAg titers over time 2
  • Persistent normalization of serum ALT levels 2
  • Older age and prior HBeAg clearance 1

Clinical Phases Leading to HBsAg Loss

The pathway typically follows this sequence:

  • Initial HBeAg clearance occurs at 8-12% per year in adults with elevated ALT 1
  • After HBeAg seroconversion, 67-80% of carriers enter the "inactive carrier state" with low/undetectable HBV DNA and normal ALT 1
  • From the inactive carrier state, approximately 0.5% annually progress to complete HBsAg clearance 1

Important caveat: HBsAg clearance may follow an acute ALT elevation, with HBsAg disappearing within 6 months (mean 70 days) after the flare 3, 2

Critical Post-Clearance Considerations

HBsAg negativity does NOT equal complete viral eradication:

  • Low levels of HBV DNA remain detectable by PCR in up to 50% of patients after HBsAg disappearance 1
  • Covalently closed circular DNA (cccDNA) persists in hepatocytes even after HBsAg clearance 4
  • Patients remain at risk for HBV reactivation if subsequently immunosuppressed 1, 4

Long-term complications can still occur:

  • Hepatocellular carcinoma can develop even after HBsAg clearance, particularly if HBV DNA persists 1, 3
  • Active liver disease (chronic active hepatitis, cirrhosis) may progress despite HBsAg negativity 3
  • The risk of hepatic decompensation decreases but is not eliminated 1

Treatment-Related HBsAg Loss

Antiviral therapy can accelerate HBsAg clearance:

  • Nucleos(t)ide analogue (NA) therapy: HBsAg loss achieved in some patients, with medium HBsAg (MHBs) becoming undetectable approximately 12.8 months before total HBsAg loss 5
  • Pegylated interferon therapy: HBsAg decline at week 12 predicts treatment response 6, 7
  • HBsAg levels <100 IU/mL for six consecutive months may predict sustained response after treatment cessation 7

Monitoring After HBsAg Clearance

Continued surveillance remains essential:

  • Monitor for HBV DNA by PCR, as low-level viremia may persist 1, 3
  • Screen for hepatocellular carcinoma if prior cirrhosis or advanced fibrosis existed 1, 3
  • Check anti-HBs development, though this does not guarantee complete protection against reactivation 1
  • Before any immunosuppressive therapy, test HBV DNA even in HBsAg-negative/anti-HBc-positive patients 4

Common pitfall: Assuming HBsAg clearance means complete cure and discontinuing all monitoring—this can miss late complications including HCC and reactivation during immunosuppression 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HBV DNA Testing for Patients with Past Hepatitis B Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

HBsAg quantification: useful for monitoring natural history and treatment outcome.

Liver international : official journal of the International Association for the Study of the Liver, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.